输血相关急性肺损伤诊治中国专家共识（2023版）

doi:10.3969/j.issn.1671-2587.2023.05.001

临床输血与检验 ›› 2023, Vol. 25 ›› Issue (5): 577-585.DOI: 10.3969/j.issn.1671-2587.2023.05.001

• 专家共识 • 下一篇

输血相关急性肺损伤诊治中国专家共识（2023版）

《输血相关急性肺损伤诊治中国专家共识》编写组

收稿日期:2023-10-09 出版日期:2023-10-20 发布日期:2023-11-20
通讯作者: 周吉成（广西医科大学第一附属医院血液科、输血科）,主要从事血液病学、输血医学研究,（E-mail）z1964jc@126.com。
作者简介:周吉成（广西医科大学第一附属医院血液科、输血科）,于洋（解放军总医院第一医学中心输血医学科）,夏荣（复旦大学附属华山医院输血医学科）,骆群（解放军总医院第五医学中心输血医学科）,潘健（《临床输血与检验》杂志编辑部）,周树生（中国科学技术大学附属第一医院急诊医学科）,黄凯（广西医科大学第一附属医院心血管内科）

Received:2023-10-09 Online:2023-10-20 Published:2023-11-20

摘要/Abstract

摘要： 输血相关急性肺损伤（transfusion-related acute lung injury ,TRALI) 是导致输血相关死亡的主要原因之一,是值得临床关注的输血反应。《输血相关急性肺损伤诊治中国专家共识》编写组组织我国包括输血医学科、血液科、重症医学科及心血管内科等领域的专家学者制订了《输血相关急性肺损伤诊治中国专家共识（2023版）》,该共识就TRALI相关的辅助检查、TRALI的诊断与鉴别诊断、TRALI的预防策略及TRALI的治疗策略提出了中国专家共识意见。

关键词: 输血相关急性肺损伤, 诊断, 预防, 治疗, 专家共识

中图分类号:

R457

《输血相关急性肺损伤诊治中国专家共识》编写组. 输血相关急性肺损伤诊治中国专家共识（2023版）[J]. 临床输血与检验, 2023, 25(5): 577-585.

参考文献

[1] KULDANEK S A,KELHER M,SILLIMAN C C.Risk factors,management and prevention of transfusion-related acute lung injury:a comprehensive update[J].Expert Rev Hematol,2019,12(9):773-785.
[2] VLAAR A,KLEINMAN S.An update of the transfusion-related acute lung injury (TRALI) definition[J].Tjh,2019,36(4):282-283.
[3] VLAAR A P J,KLEINMAN S.An update of the transfusion-related acute lung injury (TRALI):a proposed modified definition and classification scheme definition[J].Indian J Hematol Blood Transfus,2020,36(3):556-558.
[4] MÜLLER MARCELLA C A,DANIELLE V S,BINNEKADE JAN M,et al.Low-risk transfusion-related acute lung injury donor strategies and the impact on the onset of transfusion-related acute lung injury:a meta-analysis[J].Transfusion,2015,55(1):164-75.
[5] FOOD AND DRUG ADMINISTRATION.Fatalities Reported to FDA Following Blood Collection and Transfusion Annual Summary for FY2021.[EB/OL].(2023-09-25) [2022-10-24].https://www.fda.gov/media/172382/download?attachment.
[6] VLAAR ALEXANDER P J,PEARL T,MARK F,et al.A consensus redefinition of transfusion-related acute lung injury[J].Transfusion,2019,59(7):2465-2476.
[7] MAGOON R,WALIAN A,KOHLI J K,et al.Characterisin g TRALI:newer insights![J].Anaesth Crit Care Pain Med,2020,39(5):635-636.
[8] VAN WONDEREN S F,KLANDERMAN R B,VLAAR A P J.Understanding transfusion-related acute lung injury (TRALI) and its complex pathophysiology[J].Blood Transfus,2022,20(6):443-445.
[9] ZEEUW VAN DER LAAN EAN, VAN DER VELDEN S, PORCELIJN L, et al.Update on the pathophysiology of transfusion-related acute lung injury[J].Curr Opin Hematol.2020; 27(6):386-391.
[10] TOY P.Update on transfusion-related acute lung injury[J].Clin Adv Hematol Oncol,2019,17(7):378-381.
[11] DE CLIPPEL D,EMONDS M P,COMPERNOLLE V.Are we underestimating reverse TRALI?[J].Transfusion,2019,59(9):2788-2793.
[12] PETERS A L,VAN DE WEERDT E K,PRINSZE F,et al.Donor characteristics do not influence transfusion-related acute lung injury incidence in a secondary analysis of two case-control studies[J].Transfus Clin Biol,2019,26(1):10-17.
[13] TUNG J P,CHIARETTI S,DEAN M M,et al.Transfusion-related acute lung injury (TRALI):potential pathways of development,strategies for prevention and treatment,and future research directions[J].Blood Rev,2022,53:100926.
[14] MIDDELBURG RUTGER A,DANIËLLE V S,ERNEST B,et al.The role of donor antibodies in the pathogenesis of transfusion-related acute lung injury:a systematic review[J].Transfusion,2008,48(10):2167-76.
[15] CAO,JIA,ZHU.BNP and NT-proBNP as diagnostic biomarkers for cardiac dysfunction in both clinical and forensic medicine[J].Int J Mol Sci,2019,20(8):1820.
[16] CUNNINGHAM J W,MYHRE P L.NT-proBNP response to HeartFailureTherapies[J].J Am Coll Cardiol,2021,78(13):1333-1336.
[17] FARNSWORTH C W,BAILEY A L,JAFFE A S,et al.Diagnostic concordance between NT-proBNP and BNP for suspected heart failure[J].Clin Biochem,2018,59:50-55.
[18] CENTERS FOR DISEASE CONTROL AND PREVENTION.National healthcare safety network biovigilance component haemovigilance module surveillance protocol (V2.8).[EB/OL].(2023-02-06)[2023-10-24].https://www.cdc.gov/nhsn/pdfs/biovigilance/bv-hv-protocol-current.pdf.
[19] INTERNATIONAL SOCIETY OF BLOOD TRANSFUSION WORKING PARTY ON HAEMOVIGILANCE.Transfusion-associated circulatory overload (TACO) definition(2018).[EB/OL].(2019-05-01)[2023-10-24].https://www.isbtweb.org/resource/tacodefinition.html.
[20] STORCH E K,HILLYER C D,SHAZ B H.Spotlight on pathogenesis of TRALI:HNA-3a (CTL2) antibodies[J].Blood,2014,124(12):1868-1872.
[21] BERTHOLD T,SCHUBERT N,MUSCHTER S,et al.HNA antibody-mediated neutrophil aggregation is dependent on serine protease activity[J].Vox Sang,2015,109(4):366-74.
[22] VAN STEIN D,BECKERS E A M,PETERS A L,et al.Underdiagnosing of antibody-mediated transfusion-related acute lung injury:evaluation of cellular-based versus bead-based techniques[J].Vox Sang,2016,111(1):71-8.
[23] SOUTAR R,MCSPORRAN W,TOMLINSON T,et al.Guideline on the investigation and management of acute transfusion reactions[J].Br J Haematol,2023,201(5):832-844.
[24] ANANI W,TRIULZI D,YAZER M H,et al.Relative IgA-deficient recipients have an increased risk of severe allergic transfusion reactions[J].Vox Sang,2014,107(4):389-392.
[25] GERTZ M A.Updates on the diagnosis and management of cold autoimmune hemolytic Anemia[J].Hematol Oncol Clin North Am,2022,36(2):341-352.
[26] IACOPUCCI A P M,DA SILVA PEREIRA P,PEREIRA D A,et al.Intravascular hemolysis leads to exaggerated corpus cavernosum relaxation:implication for priapism in sickle cell disease[J].FASEB J,2022,36(10): e22535.
[27] SAYLOR D M,BUEHLER P W,BROWN R P,et al.Predicting plasma free hemoglobin levels in patients due to medical device-related hemolysis[J].ASAIO J,2019,65(3):207-218.
[28] SEMPLE J W,REBETZ J,KAPUR R.Transfusion-associated circulatory overload and transfusion-related acute lung injury[J].Blood,2019,133(17):1840-1853.
[29] VAN DEN AKKER T A,GRIMES Z M,FRIEDMAN M T.Transfusion-associated circulatory overload and transfusion-related acute lung injury:a review of underreported entities with current updates[J].Am J Clin Pathol,2021,156(4):529-539.
[30] YOKOYAMA A,SAKAMOTO Y,JO T,et al.Pulmonary disease as a risk factor for transfusion-related acute lung injury[J].ERJ Open Res,2021,7(3):00039-02021.
[31] AUBRON C,HOURMANT B,MENGUY J,et al.Transfusion-related respiratory complications in intensive care:a diagnosis challenge[J].Transfus Clin Biol,2021,28(4):344-348.
[32] MARCHIORI E,HOCHHEGGER B,ZANETTI G.Transfusion-related acute lung injury:an uncommon cause of pulmonary edema[J].J Bras Pneumol,2023:e20230175.
[33] BLUMBERG N,HEAL J M,GETTINGS K F,et al.An association between decreased cardiopulmonary complications (transfusion-related acute lung injury and transfusion-associated circulatory overload) and implementation of universal leukoreduction of blood transfusions[J].Transfusion,2010,50(12):2738-2744.
[34] SILLIMAN C C,MOORE E E,KELHER M R,et al.Identification of lipids that accumulate during the routine storage of prestorage leukoreduced red blood cells and cause acute lung injury[J].Transfusion,2011,51(12):2549-2554.
[35] EDER A F,DY B A,PEREZ J M,et al.The residual risk of transfusion-related acute lung injury at the American Red Cross (2008-2011):limitations of a predominantly male-donor plasma mitigation strategy[J].Transfusion,2013,53(7):1442-1449.
[36] EDER A F,HERRON R M,STRUPP A,et al.Effective reduction of transfusion-related acute lung injury risk with male-predominant plasma strategy in the American Red Cross (2006-2008)[J].Transfusion,2010,50(8):1732-1742.
[37] LOH Y S,TAN S,KWOK M,et al.Reduction of biological response modifiers in the supernatant of washed paediatric red blood cells[J].Vox Sang,2016,111(4):365-373.
[38] KLANDERMAN R B,BULLE E B,HEIJNEN J W M,et al.Reported transfusion-related acute lung injury associated with solvent/detergent plasma - A case series[J].Transfusion,2022,62(3):594-599.
[39] YU Y H,LIAN Z Q.Update on transfusion-related acute lung injury:an overview of its pathogenesis and management[J].Front Immunol,2023,14:1175387.
[40] PEGLER J R M,CASTRO A P B M,PASTORINO A C,et al.Transfusion-related acute lung injury associated to intravenous immunoglobulin infusion in a pediatric patient[J].Einstein Sao Palo Braz,2020,18:eRC5606.
[41] IBRAHIM J,AL AMRI A,GHATASHEH G.Transfusion-related acute lung injury after immunoglobulin infusion for Kawasaki disease:a case report and literature review[J].Glob Pediatr Heath,2017,4:2333794X1774654.
[42] BAUDEL J L,VIGNERON C,PRAS-LANDRE V,et al.Transfusion-related acute lung injury (TRALI) after intravenous immunoglobulins:French multicentre study and literature review[J].Clin Rheumatol,2020,39(2):541-546.
[43] 急诊氧气治疗专家共识组.急诊氧气治疗专家共识[J].中华急诊医学杂志,2018,27(4):355-360.
[44] YANG Z G,LEI X L,LI X L.Early application of low-dose glucocorticoid improves acute respiratory distress syndrome:a meta-analysis of randomized controlled trials[J].Exp Ther Med,2017,13(4):1215-1224.
[45] 付涌水,主编.临床输血[M].第3版.北京:人民卫生出版社,2013:293-294.
[46] VAN DER GOES M C,JACOBS J W,BIJLSMA J W.The value of glucocorticoid co-therapy in different rheumatic diseases - positive and adverse effects[J].Arthritis Res Ther,2014,16(2):1-13.
[47] CAPLAN A,FETT N,ROSENBACH M,et al.Prevention and management of glucocorticoid-induced side effects:a comprehensive review[J].J Am Acad Dermatol,2017,76(1):1-9.
[48] PETERS A L,VAN STEIN D,VLAAR A P J.Antibody-mediated transfusion-related acute lung injury;from discovery to prevention[J].Br J Haematol,2015,170(5):597-614.
[49] STRAIT R T,HICKS W,BARASA N,et al.MHC class I-specific antibody binding to nonhematopoietic cells drives complement activation to induce transfusion-related acute lung injury in mice[J].J Exp Med,2011,208(12):2525-2544.
[50] KAPUR R,KIM M,ASLAM R,et al.T regulatory cells and dendritic cells protect against transfusion-related acute lung injury via IL-10[J].Blood,2017,129(18):2557-2569.
[51] TUINMAN P R,VLAAR A P,BINNENKADE J M,et al.The effect of aspirin in transfusion-related acute lung injury in critically ill patients[J].Anaesthesia,2012,67(6):594-599.
[52] 葛均波,徐永健,主编.内科学[M].第8版.北京:人民卫生出版社,2013:138-144.
[53] ISHIDA Y,NAKAZAWA K,ITABASHI T,et al.Transfusion-related acute lung injury under general anesthesia successfully treated with extracorporeal membrane oxygenation:a case report[J].Clin Case Rep,2023,11(5): e7386.
[54] 中国医师协会呼吸医师分会危重症医学专业委员会,中华医学会呼吸病学分会危重症医学学组.体外膜式氧合治疗成人重症呼吸衰竭推荐意见[J].中华结核和呼吸杂志,2019,42(9):660-684.
[55] TONNA J E,ABRAMS D,BRODIE D,et al.Management of adult patients supported with venovenous extracorporeal membrane oxygenation (VV ECMO):guideline from the extracorporeal life support organization (ELSO)[J].ASAIO J,2021,67(6):601-610.

输血相关急性肺损伤诊治中国专家共识（2023版）

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

关于本刊

作者中心

在线期刊

访问统计

联系我们

[1]	异基因造血干细胞移植临床输血专家共识起草专家组. 异基因造血干细胞移植临床输血专家共识[J]. 临床输血与检验, 2023, 25(5): 586-593.
[2]	马印图, 王凤红, 杨晓亚, 赵义曼, 刘晓娣, 董书文, 李莉华. 血浆采集机及配套管路融合多项血液治疗的技术研发^*[J]. 临床输血与检验, 2023, 25(5): 636-640.
[3]	郑思晴, 王昊. m6A修饰对于肿瘤在传统化疗和新型靶向治疗耐药中的作用研究进展^*[J]. 临床输血与检验, 2023, 25(5): 706-720.
[4]	上海市医学会输血专科分会, 上海市临床输血质控中心. 医疗机构内物流系统血液运送的应用及管理上海专家共识[J]. 临床输血与检验, 2023, 25(4): 433-438.
[5]	中国输血协会临床输血管理学专业委员会. 自体单采富血小板血浆治疗薄型子宫内膜的专家共识[J]. 临床输血与检验, 2023, 25(3): 289-296.
[6]	杨静文, 常文娇. 生物被膜感染特征及防治策略研究进展^*[J]. 临床输血与检验, 2023, 25(3): 425-432.
[7]	中国输血协会临床输血管理学专业委员会. 重型和危重型COVID-19患者血液成分安全输注专家共识^*[J]. 临床输血与检验, 2023, 25(2): 149-162.
[8]	中国输血协会免疫血液学专业委员会. 输血依赖型地中海贫血（TDT）患者临床输血中国专家共识[J]. 临床输血与检验, 2023, 25(2): 163-169.
[9]	黄蓉, 张宁洁, 郝珂, 郭天虹, 黄雪原, 谷兰, 傅云峰, 黄远帅, 王勇军, 陈秉宇, 周岚, 桂嵘. 从《AABB技术手册》（18版-20版）看国际输血技术新走向^*[J]. 临床输血与检验, 2023, 25(2): 170-179.
[10]	治疗性单采过程管理与质量控制专家共识编写组. 治疗性单采过程管理与质量控制专家共识[J]. 临床输血与检验, 2023, 25(1): 1-9.
[11]	国防科技创新特区重点项目专家组. 冰冻红细胞质量评价指标专家共识[J]. 临床输血与检验, 2022, 24(6): 681-686.
[12]	李杨, 戎瑞明. 细胞治疗在肾脏移植中的应用前景^*[J]. 临床输血与检验, 2022, 24(6): 687-692.
[13]	陈蕊, 吕孟兴, 尹加忠, 沈经纬, 熊荣, 白云艳, 周文彪, 王旭, 杨琦, 屈柯暄. 云南省地中海贫血儿童输血安全策略的研究^*[J]. 临床输血与检验, 2022, 24(6): 710-715.
[14]	汪小钰, 刘丹, 张旭晗, 孙光宇, 陈二玲, 周紫微, 薛磊, 童娟, 周莉, 郑昌成. 不同剂量伊达比星联合阿糖胞苷对60岁以下成人急性髓系白血病诱导疗效的临床研究[J]. 临床输血与检验, 2022, 24(6): 791-797.
[15]	中国输血协会临床输血学专业委员会. 非心脏外科围手术期患者血液管理专家共识（2022版）[J]. 临床输血与检验, 2022, 24(5): 545-553.